Mary-Katharine Collins1, Jacqueline F Moreau1, Dan Opel2, James Swan3, Noel Prevost4, Matthew Hastings4, Eleanor Bimla Schwarz5, Laura Korb Ferris6. 1. School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Medical student, Loyola University of Chicago School of Medicine, Chicago, Illinois. 3. Division of Dermatology, Department of Internal Medicine, Loyola University of Chicago School of Medicine, Chicago, Illinois. 4. Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: ferrislk@upmc.edu.
Abstract
BACKGROUND: Approximately 150 women annually become pregnant while taking isotretinoin despite participation in the iPLEDGE program. Noncompliance with the requirement to be abstinent or use 2 contraceptive methods may be a contributing factor. OBJECTIVE: We sought to determine the degree of adherence to contraception or abstinence among women taking isotretinoin. METHODS: We conducted an anonymous survey of women of childbearing potential taking isotretinoin for at least 2 months. RESULTS: Among 75 participants, 21 (28%) chose abstinence as their primary means of pregnancy prevention, of whom 4 (19%) were sexually active during treatment. The most commonly chosen contraceptive methods among the 39 women who were sexually active were condoms (35, 90%) and oral contraceptive pills (18, 46%). Twelve women (31%) admitted to having intercourse at least once using 1 or fewer forms of contraception; 10 failed to use condoms, and 1 reported completely unprotected intercourse. Among sexually active oral contraceptive pill users, 7 (39%) reported missing 1 or more pills in the previous month. LIMITATIONS: Data were self-reported, thus participants may have inaccurately reported contraception use. CONCLUSIONS: Encouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.
BACKGROUND: Approximately 150 women annually become pregnant while taking isotretinoin despite participation in the iPLEDGE program. Noncompliance with the requirement to be abstinent or use 2 contraceptive methods may be a contributing factor. OBJECTIVE: We sought to determine the degree of adherence to contraception or abstinence among women taking isotretinoin. METHODS: We conducted an anonymous survey of women of childbearing potential taking isotretinoin for at least 2 months. RESULTS: Among 75 participants, 21 (28%) chose abstinence as their primary means of pregnancy prevention, of whom 4 (19%) were sexually active during treatment. The most commonly chosen contraceptive methods among the 39 women who were sexually active were condoms (35, 90%) and oral contraceptive pills (18, 46%). Twelve women (31%) admitted to having intercourse at least once using 1 or fewer forms of contraception; 10 failed to use condoms, and 1 reported completely unprotected intercourse. Among sexually active oral contraceptive pill users, 7 (39%) reported missing 1 or more pills in the previous month. LIMITATIONS: Data were self-reported, thus participants may have inaccurately reported contraception use. CONCLUSIONS: Encouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.